Monitoring Monoclonal Gammopathies
Monoclonal Gammopathies: Primary Systemic Amyloidosis
November 2009
With the use of the serum M-spike and Ig quantitation and urine M-spike, there still are some patients with no measurable disease. This slide shows the serum and urine electrophoresis results for a patient with primary amyloid. There is a faint monoclonal lambda band visible in the urine immunofixation gel, but there is no M-spike to monitor this disease even though this patient has proteinuria and a life-threatening disorder.
Primary Amyloidosis |
Jump to section:
- Introduction
- Slide Images
- International Myeloma Working Group: Disease Monitoring
- Serum Protein Electrophoresis and Immunofixation Electrophoresis
- Serum and Urine Protein Electrophoresis and Immunofixation Electrophoresis
- Methods for Monitoring Monoclonal Gammopathies: 2005 IMWG
- Methods for Monitoring Monoclonal Gammopathies
- Small IgG kappa M-spike
- Large IgG kappa M-spike
- Relationship of Serum Agarose Electrophoresis M-spike and Ig Quantitation1
- Disease Monitoring
- Monoclonal Gammopathies: Primary Systemic Amyloidosis
- Free Light Chain: Antibody Specificity
- FLC κ/λ Ratio: Disease Sensitivity2
- Methods for Monitoring Monoclonal Gammopathies
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring3
- Response Criteria for FLC4,5
- Receiver Operator Curve (ROC): % FLC Reduction vs. Overall Hematologic Response6
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document